Cargando…
Physicochemical and biological evaluation of JR-131 as a biosimilar to a long-acting erythropoiesis-stimulating agent darbepoetin alfa
Renal anemia is predominantly caused by a relative deficiency in erythropoietin (EPO). Conventional treatment for renal anemia includes the use of recombinant human EPO (rhEPO) or a long-acting erythropoiesis-activating agent named darbepoetin alfa, which is a modified rhEPO with a carbohydrate chai...
Autores principales: | Tani, Junya, Ito, Yae, Tatemichi, Satoshi, Yamakami, Makoto, Fukui, Tsuyoshi, Hatano, Yukichi, Kakimoto, Shinji, Kotani, Ayaka, Sugimura, Atsushi, Mihara, Kazutoshi, Yamamoto, Ryuji, Tanaka, Noboru, Minami, Kohtaro, Takahashi, Kenichi, Hirato, Tohru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7164597/ https://www.ncbi.nlm.nih.gov/pubmed/32302352 http://dx.doi.org/10.1371/journal.pone.0231830 |
Ejemplares similares
-
JR‐131, a Biosimilar of Darbepoetin Alfa, for the Treatment of Hemodialysis Patients With Renal Anemia: A Randomized, Double‐Blinded, Parallel‐Group Phase 3 Study
por: Nishi, Shinichi, et al.
Publicado: (2019) -
Long‐Term Safety and Efficacy of JR‐131, a Biosimilar of Darbepoetin Alfa, in Japanese Patients With Renal Anemia Undergoing Hemodialysis: Phase 3 Prospective Study
por: Nishi, Shinichi, et al.
Publicado: (2019) -
Iron status and erythropoiesis response to darbepoetin alfa in dogs with
chronic kidney disease
por: BHAMARASUTA, Chayanont, et al.
Publicado: (2021) -
Extended dosing of darbepoetin alfa in peritoneal dialysis patients
por: Feriani, Mariano, et al.
Publicado: (2011) -
Flexible dosing with Darbepoetin alfa for the treatment of chemotherapy-induced anemia
por: Wauters, Isabelle, et al.
Publicado: (2006)